Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Bacteria or actinomycetales

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424930100 - WHOLE LIVE MICRO-ORGANISM, CELL, OR VIRUS CONTAINING

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424930450 Lactobacillus or Pediococcus or Leuconostoc 207
424930460 Bacillus 80
424930440 Streptococcus 65
424930410 Clostridium 20
424930420 Staphylococcus 15
424930480 Enterobacteriaceae 6
424930470 Pseudomonas 5
20090324564MICROORGANISM CAPABLE OF CONTROLLING PLANT DISEASES AND PLANT DISEASE-CONTROLLING AGENT USING THE MICROORGANISM - The object of the present invention is to provide a microorganism which places little burden on the environment, shows an extremely low possibility of a resistant pathogenic bacterium to emerge, and has a superior controlling ability against various plant diseases (in particular, soft rot and canker of leaf and root vegetables); a plant disease controlling agent containing the microorganism; and a method for controlling plant diseases comprising applying the plant disease controlling agent to the plant and/or the grove soil thereof. A plant disease controlling agent is used which contains a bacterial cell of 12-31-2009
20130121978CHEMICAL AND BIOLOGICAL AGENTS FOR THE CONTROL OF MOLLUSCS - Compositions and methods for controlling molluscs, members of the Gastropoda and Bivalvia classes which includes but is not limited to lactones, lactams, carbamates, amides, and/or carboxylic acid containing compounds as active ingredients and/or compounds derived from 05-16-2013
20110097311COMPOSITION HAVING BIOCIDE ACTIVITY FOR AQUEOUS PREPARATIONS - The present invention refers to a process for bacterial stabilizing aqueous preparations like e.g. calcium carbonate slurries and a composition which can be used for the biocidal treatment of such aqueous preparations.04-28-2011
20100092443NOVEL COMBINATIONS OF NITROGENATED HETEROCYCLIC ANTIBACTERIAL COMPOUNDS WITH OTHER ANTIBACTERIAL COMPOUNDS AND THE USE OF SAME AS DRUGS - The invention relates to the combination of nitrogenated heterocyclic antibacterial compounds of formula (I) with other antibacterial compounds and the use of same as drugs.04-15-2010
20110236361EFFECTIVE CONTROL OF VIRAL PLANT DISEASE WITH STRAINS OF PSEUDOMONAS OLEOVORANS - A strain of 09-29-2011
424930430 Streptomyces 3
20100260733NOVEL ANTI AGING AGENTS AND METHODS TO IDENTIFY THEM - The present invention discloses novel mechanisms in the aging process and describes novel methods for high-throughput screening to identify, detect, and purify agents to be used for improving mitochondrial function, maintaining the cell cycle-arrested state in senescent and post mitotic cells, and thus preventing or treating age-related diseases or disorders associated with accelerated mitochondrial function loss, telomere dysfunction, and/or deterioration of the growth-arrested state. The present invention also discloses a number of compounds or compositions identified from this method. The present invention further provides the use of low doses of rapamycin or its analogs as a mimic of caloric restriction in preventing age-related diseases or disorders.10-14-2010
20110189143FORMULATION AND METHOD FOR TREATING PLANTS TO CONTROL OR SUPPRESS A PLANT PATHOGEN - The present invention provides formulations and methods for preventing, suppressing, treating, or controlling pre- or post-harvest disease or decay in plants. In the inventive method, plants are contacted with a formulation including an antagonistic microorganism and a booster composition. The booster composition generally includes about 3 parts Kaolin clay, about 1 part yeast, about 1 part Yucca plant extract, and about 1 part calcium-source material. The antagonistic microorganism may be included in an amount of between about 0.02 parts and about 0.5 parts by weight of the formulation, with about 0.04 parts antagonistic microorganism being preferred in testing to date. The formulation is typically applied to the above ground structures of the plant, including its leaves, flowers, stems, trunk, blossoms and fruit.08-04-2011
20120093791STIMULATION OF INNATE IMMUNITY WITH AN ANTIGEN FROM BACTERIAL ORIGIN - There is provided a method of attenuating a respiratory infection in a subject, use of a composition for the manufacture of a medicament and a composition for treating respiratory infections comprising a preparation of 04-19-2012
Entries
DocumentTitleDate
20090123429ARTHROSPIRA-BASED COMPOSITIONS AND USES THEREOF - The present invention concerns a composition comprising physiologically stressed 05-14-2009
20080260695Composition for prevention and/or treatment of cancer - The invention relates to a composition for use in the prevention and treatment of cancer. The composition includes fermented soy extract, oligomeric proanthocyanidin, epigallocatiechin gallate, spirulina, curcumin and 10-23-2008
20110195051USE OF BACTERIA OF THE GENUS TENACIBACULUM FOR QUORUM QUENCHING - Use of bacterial cells of the genus 08-11-2011
20100074872COMPOSITIONS AND METHODS FOR CHARACTERIZING AND RESTORING GASTROINTESTINAL, SKIN, AND NASAL MICROBIOTA - The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant 03-25-2010
20100074871Probiotic infant products - The present invention is directed to an infant formula or children's nutritional product comprising a protein source, a fat source, a carbohydrate source, and 03-25-2010
20100074873Live bacteria product - A live bacteria product including dormant viable bacteria suspended in a liquid carrier. The liquid carrier is sufficiently devoid of moisture so that substantially all of the bacteria will remain in a dormant state for several months or until applied to the target host. The liquid carrier has a moisture content of less than one percent and preferably has a moisture content of less than one-tenth of one percent. The carrier contains mineral oil and a suspension agent and may also include an adsorbent. The suspension agent may be polymers such as synthetic polymers. The product is stored and shipped in a plastic bag and is sprayed onto its target host or the like. The moisture and pH of the target host then activates the bacteria.03-25-2010
20120183506PREVENTION AND TREATMENT OF ALLERGIC DIARRHOEA - This invention relates to 07-19-2012
20130084265DELIVERY SYSTEM FOR BIOLOGICAL COMPONENT - A controlled release delivery system composition and method applied to humans and animals, for oral, anal or vaginal administration of a biological component is disclosed. Preferably, a bacterium is delivered, and more preferably the bacterium is probiotic in nature, however, the biological component is not limited to the bacterium.04-04-2013
20090004148Novel Probiotic - The present invention relates to a novel Gram positive species that has been isolated from the porcine intestine. The Gram positive bacterium of the invention has unprecedented properties that relate to its capacity to grow on a wide range of industrial feeds including oligosaccharide carbohydrates both in vitro and in vivo in animals. The Gram positive bacterium of the invention may be used alone as probiotic or in synbiotic combination with oligosaccharide carbohydrates. Specific applications include the promotion of health, growth performance and colonization resistance in monogastric animals.01-01-2009
20090060877Use - Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of Type II diabetes and/or obesity and methods of treating or preventing Type II diabetes and/or obesity in a subject by administering an effective amount of a composition comprising a whole cell of a bacterium from a genera of aerobic organisms in the order of Actinomycetales to said subject. Preferably the bacteria is from one or more of the following genera for example: 03-05-2009
20120164109 NUTRITIONAL COMPOSITION COMPRISING BIFIDOBACTERIUM LONGUM STRAINS AND REDUCING FOOD ALLERGY SYMPTOMS, ESPECIALLY IN INFANTS AND CHILDREN - A complete nutritional composition comprising 06-28-2012
20130028869FEED SUPPLEMENT COMPRISING OLIGOSACCHARIDES AND MEDIUM CHAIN FATTY ACIDS - The present invention relates to a feed supplement and a feed containing this feed supplement, comprising 1) a homotrimer, heterotrimer, homotetramer and/or heterotetramer of a carbohydrate component selected from the group consisting of a pentose saccharide, a hexose saccharide, glucuronic and galacturonic acid, and 2) a medium-chain fatty acid (MCFA), selected from the group consisting of caproic acid (C6), caprylic (C8), capric (C10) and lauric acid (C12). The invention also refers to the use of the feed supplement or feed in order to improve the efficiency of animal production, such as weight gain, feed conversion, nutritive value, health and wellbeing through the selective elimination of enteropathogens.01-31-2013
20090092585Canine probiotic bifidobacteria pseudolongum - According to the invention there is provided a strain of lactic acid bacteria of the species 04-09-2009
20100055073TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS - An orally administrable nutritional formulation for use in the treatment of Pervasive Developmental Disorders (e.g. Autism, Asperger disorder or Retts disorder) contains free amino acids as the sole source of protein. The formulation may be administered to the patient as the sole daily source of protein or as a supplemental source of protein03-04-2010
20090041728Proteoglycan Degrading Mutants for the Treatment of CNS - The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.02-12-2009
20090041727Compositions and Methods for Microbe Storage and Delivery - The present invention relates to the field of bacteriology. In particular, the invention relates to compositions of probiotic microbes and methods for making and using such compositions, e.g. in the treatment and prevention of catheter associated urinary tract infections.02-12-2009
20130058898LACTIC ACID BACTERIUM-CONTAINING PREPARATION - The present invention provides very safe lactic acid bacteria and lactic acid bacteria preparations which are effective in prevention and therapy of allergies and/or in lowering of the blood neutral fat level. The present invention also provides pharmaceutical products and food or drink products which contain, as an active ingredient, a composition that contains cultured cells of the lactic acid bacterium 03-07-2013
20110014156Bifidobacterium for dust mite allergy - A composition comprising 01-20-2011
20090269307Edible Product Containing Ginseng Polysaccharides and Beneficial Bacteria - One aspect of the present invention relates to an edible product containing: • probiotic bacteria in an amount of at least 1010-29-2009
20120225037Sporulation-Deficient B. texasporus Cells and Methods for Efficient and Cost-effective Inactivation and Use Thereof - Novel strains and methods for their use are provided. Particularly, foods and other oral products or treatments containing sporulation-deficient 09-06-2012
20090252709NOVEL BACTERIUM BELONGING TO THE GENUS BIFIDOBACTERIUM AND UTILIZATION OF THE SAME - It is intended to provide 10-08-2009
20090010892Hyperlipidemia Treatment Agent - To provide a cholesterolemia treatment agent comprising, as an active ingredient, a bacterial mixture of three bacterial types consisting of lactic acid bacteria, butyric acid bacteria, and glycation bacteria which are effective in lowering serum cholesterol. And to provide a triglyceridemia treatment agent comprising, as an active ingredient, a bacterial mixture of three bacterial types consisting of lactic acid bacteria, butyric acid bacteria, and glycation bacteria which are effective in lowering triglycerides.01-08-2009
20090010891Sepsis Treatment Agent - To provide a bacterial translocation preventive for humans and animals comprising a probiotics formulation which has lactic acid bacteria, butyric acid bacteria, and saccharifying bacteria as the main components thereof. And to provide a sepsis treatment agent for humans and animals comprising a probiotics formulation which has lactic acid bacteria, butyric acid bacteria, and saccharifying bacteria as the main components thereof.01-08-2009
20090010890STORAGE STABLE COMPOSITIONS OF BIOLOGICAL MATERIALS - Storage stable compositions of biological materials, including bioactive biological materials are provided in the form of a water-in-oil emulsion, comprising: 01-08-2009
20100074870Probiotic infant products - The present invention is directed to an infant formula or children's nutritional product comprising a protein source, a fat source, a carbohydrate source, and 03-25-2010
20120237482METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS BY MODULATION OF MICROGLIAL ACTIVATION - Methods for treatment of neurological disorders with respect to microglial activation are presented herein. Other examples and related pharmaceutical combinations and compositions are also described herein.09-20-2012
20100143307Use of Penicillin G Procaine as a selective antimicrobial agent in the production of alcohol by fermentation - A process for the use of low concentration levels of Penicillin G Procaine to eliminate or control the growth of unwanted or undesirable bacteria (contaminating bacteria) in the fermentation production of alcohol without inhibition of the growth or replication of the yeast.06-10-2010
20080274085Probiotic Bifidobacterial Species - A probiotic composition comprising a 11-06-2008
20090148413Method for treatment of irritable bowel syndrome - A composition and method for treatment for bowel disorders is described. The composition consists of three parts. The first part is a highly purified, insoluble, chemically unmodified fiber from plants which is mixed with an aqueous solution such as water. The second part of the composition is a commercially available probiotic preparation. These commercially probiotic preparations contain large numbers of viable microorganisms of either 06-11-2009
20110293570ISOLATION OF NOVEL BACTERIA CONTRIBUTING TO SOILBORNE DISEASE SUPPRESSION - Embodiments relate to plant disease suppressive microorganisms and compositions including the same, methods for isolating disease suppressive microorganisms, and methods for controlling plant diseases using disclosed compositions and microorganisms.12-01-2011
20110300110ENAMINOCARBONYL COMPOUND/BENEFICIAL ORGANISM COMBINATIONS - The novel combinations of enaminocarbonyl compounds and beneficial species comprising, firstly, at least one enaminocarbonyl compound of the formula (I)12-08-2011
20110300109COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention is based, in part, on our discovery of compositions and methods that can be used to systemically deplete arginine and thereby treat arginine-dependent cancers. Our studies indicate that administering a composition that depletes arginine directly to the patient's small intestine will provide effective treatment for arginine-dependent cancers. Moreover, the methods can be carried out in such a way that various sources of arginine are restricted and side effects are minimized. For example, to deplete arginine, one can not only administer an arginine-depleting enzyme directly to the intestinal lumen but can also inhibit endogenous production of arginine, reduce arginine production by intestinal bacteria and limit arginine intake. To minimize side effects, one can inhibit protein breakdown, which may occur as a compensatory mechanism, provide systemic NO from a nitric oxide donor, provide a pressor peptide, and/or provide prostacycline or an analog thereof.12-08-2011
20090297482PROBIOTIC STRAIN AND ANTIMICROBIAL PEPTIDE DERIVED THEREFROM - The invention relates to a strain of 12-03-2009
20090148414Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same - The present invention relates to compositions comprising at least about 8% β-glucans and/or at least about 8% α-fucans, which has a prebiotic effect and act as a replacement for in-feed antibiotics. The present invention also relates to extraction methods to obtain such extracts and various uses for the compositions comprising β-glucans and/or α-fucans.06-11-2009
20100104536P38 INHIBITORS - The invention relates to novel p38 MAPK inhibitor which involves 04-29-2010
20090162324Use of Whole Cell Actinomycetales Bacteria to Treat Stress-Induced Pulmonary Haemorrhage - Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of stress-induced pulmonary haemorrhage (SIPH), preferably exercise induced pulmonary haemorrhage (EIPH), and methods of treating or preventing SIPH, preferably EIPH, in a subject by administering an effective amount of a composition comprising a whole cell of a bacterium from a genera of aerobic organisms in the order of Actinomycetales to said subject. Preferably the aerobic organism is from one or more of the following genera for example: 06-25-2009
20090317363Cytokine Derivatives - The invention relates to polypeptides comprising an N-terminal portion and a C-terminal portion, wherein said N-terminal portion comprises the signature sequence QGP[P or L] and the amino acid sequence of said C-terminal portion is at least 70% identical to SEQ ID NO: 1, and uses thereof.12-24-2009
20090317364NOVEL COMPOSITIONS FOR PREVENTION AND TREATMENT OF MASTITIS AND METRITIS - A novel stable synergistic compositions used for the prevention and/or treatment of mastitis and metritis in mammals comprising a combination of therapeutically effective amount of 12-24-2009
20100015097METHOD OF MAKING SORBENT, THE SORBENT OBTAINED BY THIS METHOD AND THE USES OF THE SORBENT AS FEED ADDITIVE AND MEDICINE - The present invention relates to a method of making a sorbent, comprising the steeps of crushing seed husks, acid hydrolysis with extraction of water-soluble ballast substances and formation of the target composition of lignin, cellulose and melanin, water rinsing and drying, wherein the acid hydrolysis is made with an 0.1-36% acid solution during 0.3-4.5 hours in the boiling mode under pressure in the range 0.1-0.7 MPa, rinsing is made with water and/or a 0.1-1.0% alkali solution and then softened water, and the product is subsequently dried. The sorbent comprises a porous multilevel matrix on the basis of lignin, cellulose and melanin. The invention further discloses the sorbent and its uses as for prophylaxis and treatment of toxicoses, free-radical pathologies, diarrhea syndromes which are caused by ecotoxicants, viral and bacterial infections, for prophylactic and treatment of animal diseases caused by mycotoxins, pesticides, bad-quality forages in all kinds of animals.01-21-2010
20100119488PROBIOTICS TO IMPROVE GUT MICROBIOTA - The use of 05-13-2010
20080260696Method for decreasing inflammation and oxidative stress in mammals - The present invention is directed to a method for decreasing inflammation and oxidative stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to decrease a level of an oxidized glutathione and/or increase the ration of reduced glutathione to oxidized glutathione in the blood of the mammal subsequent to administration of the glucose anti-metabolite.10-23-2008
20100086521Means For Regulating The Cosmetic Appearance And/Or Health Of Human Keratinous Tissue - Regulating human keratinous tissue (e.g., skin, hair, and/or nails). More particularly, the invention relates to regulating the cosmetic appearance and/or health of human keratinous tissue by orally administering a dietary supplement comprising a probiotic to a human. In another aspect, the invention also relates to a method of marketing, an article of commerce, and a personal care kit.04-08-2010
20120107280BIOFUNGICIDAL COMPOSITION FOR CONTROLLING PHYTOPATHOGENIC FUNGI - Biofungicide composition derived from a biologically pure culture of a Chilean bacterial isolate obtained from the skin of grapes, corresponding to 05-03-2012
20120107279PREVENTION AND TREATMENT OF ROTAVIRUS DIARRHOEA - This invention relates to 05-03-2012
20090263356ANTI-ANGIOGENIC COMPOSITION COMPRISING GRAIN-DERIVED COMPONENT AS ACTIVE INGREDIENT - It is an object of the invention to provide a composition with an excellent action of inhibiting vascularization, as prepared by a simple method suitable for actual production from an inexpensive, relatively readily available material without any problematic safety profile at an industrial scale without any complicated purification step. The composition is a composition for inhibiting vascularization, which contains a barley-derived ingredient selected from the group consisting of an unpolished barley ethyl alcohol extract fraction, an unpolished barley alkali extract fraction and fermented barley (preferably, a residual solution from the distillation of barley distilled spirits) as the active component with an action of inhibiting vascularization. The composition for inhibiting vascularization is a composition for therapeutically treating or preventing diseases which vascularization should be inhibited, specifically diseases with an etiology of abnormal vascularization in tumor or cancer, chronic inflammation or retinopathy. The composition is in a form selected from the group consisting of food additives, food materials, foods and drinks, pharmaceutical products under regulations by the Ministry of Health and Labor in Japan and quasi-pharmaceutical products under regulations by the Ministry of Health and Labor in Japan, and feeds.10-22-2009
20090274661USE OF BIFIDOBACTERIUM LONGUM FOR THE PREVENTION AND TREATMENT OF INFLAMMATION - The invention relates to the use, in the manufacture of a medicament or a therapeutic nutritional composition for preventing or reducing inflammation in a mammal, of 11-05-2009
20090142304Composition for Improving Intestinal Flora - A composition provided by the present invention for improving intestinal microflora includes 1-kestose as an active ingredient. The present invention further provides a lactic acid bacteria proliferating agent including 1-kestose as an active ingredient, which proliferates 06-04-2009
20090110664PROBIOTIC COMPOSITIONS AND METHODS FOR INDUCING AND SUPPORTING WEIGHT LOSS - A probiotic composition for inducing or supporting weight loss in a subject, the probiotic composition including an effective amount of a bacteria selected from the genus 04-30-2009
20090274662Methods And Kits For The Treatment Of Inflammatory Bowel Disorder Conditions - The present invention comprises methods and kits that are useful for the treatment an inflammatory bowel disease. The methods comprise administering to a mammal in need of treatment a composition comprising an active agent in combination with a probiotic and/or optionally an antibiotic.11-05-2009
200902800915-FLUOROURACIL-RESISTANT BACTERIA AND METHOD FOR PRODUCTION THEREOF - The present invention provides a method for producing a cytosine deaminase (CD)-expressing, 5-fluorouracil (5-FU)-resistant microorganism which can grow in anaerobic tumor tissues, can express CD, and has a resistance to 5-FU at a concentration that is at least effective for antitumor activity. More specifically, the method is a method (A) comprising performing subculture or acclimation culture of a CD-expressing microorganism which can grow in anaerobic tumor tissues, in the presence of 5-fluorocytosine (5-FC), or a method (B) comprising (1) performing subculture or acclimation culture of a microorganism which can grow in anaerobic tumor tissues and does not express CD, in the presence of 5-FU to produce a 5-FU-resistant microorganism and (2) transforming the 5-FU-resistant microorganism by introducing a CD gene. The present invention also provides the CD-expressing, 5-FU-resistant microorganism and a pharmaceutical composition comprising the microorganism.11-12-2009
20100278781NUTRITION WITH NON-VIABLE BIFIDOBACTERIUM AND NON-DIGESTIBLE OLIGOSACCHARIDE - An infant and/or toddler nutrition comprising non-viable 11-04-2010
20110268703PROBIOTIC STRAIN AND ANTIMICROBIAL PEPTIDE DERIVED THEREFROM - A strain of 11-03-2011
20080213226COMPOSITIONS INCLUDING AMMONIA OXIDIZING BACTERIA AND METHODS OF USING SAME - A preparation and method for treating a subject how had developed or is at risk of developing at least one of high blood pressure, Alzheimer's Disease, obesity, and Diabetes Type II, Sickle Cell Anemia, Preeclampsia, Sudden Infant Death Syndrome, or Vascular disease comprising positioning ammonia oxidizing bacteria close proximity of a surface of the subject, of nitric oxide and nitric oxide precursors using ammonia oxidizing bacteria.09-04-2008
20090169517Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules - The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).07-02-2009
20100129323Novel Shuttle Vector - The present invention provides a shuttle vector for a microorganism of the genus 05-27-2010
20080286240Ecologically Protected Material - The present invention relates to an ecological protected material, comprising a base material (11-20-2008
20110206642Preventing obesity-related metabolic syndrome with melagonesis - Anti-inflammatory effect of α-MSH-like compounds can be employed for curtailing sequelae of obesity and overweight. Importantly, molecular compounds that stimulate melanin biosynthesis by mimicking the effects of α-MSH are readily available for trials aimed at control of metabolic syndrome components. Synthetic agonists of α-MSH receptors, melanotan II and bremelanotide, have already been proven safe in human trials for therapeutic tanning and some non-obesity-related diseases.08-25-2011
20090081167FOLIC ACID PRODUCING BIFIDOBATERIUM BACTERIAL STRAINS, FORMULATIONS AND USE THEREOF - The present invention relates to folic acid-producing bacterial strains belonging to the genus 03-26-2009
20110206641STRESS TOLERANT BIFIDOBACTERIA - The present invention relates in general to the field of Bifidobacteria. In particular the present invention relates to the field of Bifidobacteria with a modulated stress resistance. One embodiment of the present invention is a 08-25-2011
20090162322Oral administration form comprising probiotic bacteria - The invention relates to an oral administration form which comprises at least one species of probiotic microorganisms, where it itself and/or the probiotic bacteria is/are provided with a coating which comprises at least two cellulose ethers.06-25-2009
20090136455Canine probiotic bifidobacteria pseudolongum - According to the invention there is provided a strain of lactic acid bacteria of the species 05-28-2009
20130121968Methods of combining metagenome and the metatranscriptome in multiplex profiles - The present invention describes changes in bacterial gastrointestinal, cutaneous and nasal microbiota associated various mammalian medical conditions. Described are diagnostic tests that arise from combining phylogenetic information about the families, genus, and species of the microbiome and their relative abundance with the metabolic information contained in the metatranscriptome to determine the presence and absence of a disease or medical condition. Provided are compositions of bacteria, co-cultures of bacteria and a carrier for use in treating the disclosed medical conditions. The described compositions restore or correct disease- or medical condition-related imbalances in the microbiome profile with culture-conditioned formulations in which the transcriptome activity of the administered organisms is optimized. Alternatively, formulations of metabolites that drive changes in the metatranscriptome native to the mammal that treat disease or a medical condition or restore health are taught.05-16-2013
20090142303METHODS AND COMPOSITIONS FOR DRIED CELLULAR FORMS - Methods and compositions of spray drying cellular material are provided that allow preservation of the cellular material. In one aspect, the cellular material is spray dried with a quantity of excipient. In another aspect, the cellular material is spray dried using a cryoprotectant.06-04-2009
20090098088Methods And Kits For The Treatment Of Diverticular Conditions - The present invention relates to methods and kits that are useful for the treatment of diverticular disease, diverticulitis, and combinations thereof. The methods comprise administering to a mammal in need of treatment a composition comprising a probiotic, either alone or in combination with an anti-inflammatory or an antibiotic.04-16-2009
20090010893Canine probiotic Bifidobacteria globosum - According to the invention there is provided a strain of lactic acid bacteria of the species 01-08-2009
20090004147Composition for a healthy gastrointestinal tract - The composition combines Zinc Carnosine; Beta Carotene; Vitamin A; Copper; Calcium Ascorbate; White Tea; Fructo-oligosaccharides; and Probiotic (01-01-2009
20090246177MEGASPHAERA ELSDENII STRAIN AND ITS USES - This invention relates to a novel strain of 10-01-2009
20120141423NOVEL PAENIBACILLUS POLYMYXA STRAIN, ANTIBIOTIC ANTIMICROBIAL AGENTS AND METHODS OF THEIR USE - The present invention relates to a novel 06-07-2012
20100266550MAMMALIAN MILK MICROORGANISMS, COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF MASTITIS - The present invention relates to a novel approach to prevent or treat mastitis both in humans and animals through the use of mammal milk-derived microorganisms obtained from healthy hosts of the homologous species; to those new probiotic microorganisms obtained from milk able to reduce infectious mastitis and the method of screening used for their obtaining; to the use of these probiotic bacteria for the prophylaxis or treatment against mastitis and other diseases; and finally, to compositions comprising these compounds.10-21-2010
20100150874PROBIOTICS TO REDUCE DEVELOPMENT OF ALLERGY IN INFANTS BORN BY CAESAREAN SECTION - The use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for reducing the risk of subsequent development of allergy in infants delivered by caesarean section.06-17-2010
20100260720PREVENTION OF OPPORTUNISTIC INFECTIONS IN IMMUNE-COMPROMISED SUBJECTS - This invention relates to a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic 10-14-2010
20100239537BACTERIAL ISOLATE AND METHODS FOR DETOXIFICATION OF TRICHOTHECENE MYCOTOXINS - The invention provides a bacterial isolate defined by accession number 180507-1 filed with the International Depository Authority of Canada. The bacteria are capable of degrading trichothecene mycotoxins. Also provided are compositions comprising the bacteria and methods of preventing or treating food, foodstuffs, crops and harvested crops that are contaminated or susceptible to contamination with trichothecene mycotoxins. Kits are also provided.09-23-2010
20100254948PROCESS FOR THE PREPARATION OF GAMMA-AMINO BUTYRIC ACID (GABA) BY THE USE OF LACTIC ACID BACTERIA (LAB) ON AGRO-AND FOOD-INDUSTRY SURPLUS - This invention relates to a process for the production of gamma-aminobutyric acid (GABA) from 10-07-2010
20100233129PREVENTION AND TREATMENT OF SECONDARY INFECTIONS FOLLOWING VIRAL INFECTION - This invention relates to a synthetic nutritional composition suitable for use in the prevention of secondary infections following a viral infection characterised by neuraminidase activity comprising a sialylated oligosaccharide and N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine The invention further extends to the use of such a composition in the prevention of secondary infections such as otitis media.09-16-2010
20100254949PREBIOTIC OLIGOSACCHARIDES - The present invention provides galacto-oligosaccharide compositions that preferentially stimulate growth of specific 10-07-2010
20090074725Live organism product - A live organism product wherein the organisms are in a dormant state and are suspended in a liquid carrier which is sufficiently devoid of moisture so that the organisms will remain in a dormant state for several months. The carrier is comprised of oil. The carrier may also include an absorbent. The product is stored and shipped in a plastic bag and is sprayed onto its target host or the like. The moisture and pH then activates the organisms.03-19-2009
20100221226Use of a Bifidobacterium Strain for Preparing a Composition for Preventing and/or Treating Allergic Manifestations - The present invention relates to the use of a 09-02-2010
20110177036WHOLE BLOOD CULTURES COMPRISING STIMULATED IMMUNE CELLS, AND USE THEREOF AS MEDICAMENTS - The present invention relates to a whole-blood culture containing specific immunocompetent killer cells that are activated against tumor cells, viruses, bacteria and/or allergens, whereby the whole-blood culture consists of whole-blood and a culture medium at a ratio of 3:1 to 4:1, whereby the culture medium has an oxygen excess of at least 100% or more and contains a water-soluble emulsification product comprising a mixture of phospholipids, vitamin E, and low-molecular proteoglycans with a molecular weight of 1,200 to 12,000 Dalton, and whereby dead tumor cells or fragments thereof and/or viral and/or bacterial antigens and/or allergens have been added to the whole-blood culture [to serve] as antigen in the specific recognition process for production of the activated killer cells (stimulation). The invention also relates to a method for producing the culture, as well as stimulants for the whole-blood culture and a method for the selection thereof.07-21-2011
20130136720METHODS OF USING FUT2 GENETIC VARIANTS TO DIAGNOSE CROHN'S DISEASE - The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the FUT2 genetic locus.05-30-2013
20100172876PROTEIN FREE FORMULA - The invention relates to the use of composition comprising free amino acids as a sole source of protein, a fatty acid source comprising long chain polyunsaturated fatty acids, a carbohydrate source comprising digestible and indigestible carbohydrates, and milk protein free Bifidobacteria for treating a person suffering from (a) colic, congestion, runny nose, wheezing, vomiting, diarrhoea, bloody stools, mucus in stools, rash, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma; (b) cow's milk allergy and/or food protein intolerance; and/or (c) infections, wherein the indigestible carbohydrate is selected from a milk protein free source and the total composition is essentially free of intact proteins.07-08-2010
20090068150LACTIC ACID BACTERIA CULTURE OF MUNG BEAN AND THE PREPARATION METHOD OF THE SAME, AND THE COSMETIC COMPOSITION COMPRISING THE SAME - Disclosed is a lactic acid bacteria culture of mung bean obtained by culturing lactic acid bacteria in a culture medium containing mung bean extract. The culture contains the mung bean extract and GABA (ϝ03-12-2009
20110008291Use of antifungal compositions to treat upper gastrointestinal conditions - The present invention provides a novel method for treating oral conditions and upper gastrointestinal conditions in a subject by providing an inventive oral dosage form of a pharmaceutical composition comprising an effective amount of at least one antifungal and optionally a flavor modifier and/or salivation component such as an herbal component. In the present invention, the subjects have either not been diagnosed or do not have active or recurrent fungal infections. Specifically, the present invention is directed to chewable dosage forms.01-13-2011
20110177035USE OF SECRETOR, LEWIS AND SIALYL ANTIGEN LEVELS IN CLINICAL SAMPLES AS PREDICTORS OF RISK FOR DISEASE - An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewis07-21-2011
20100129324 BIOLOGICAL EFFECTS OF COMPOSITIONS COMPRISING ROSMARINIC ACID - The present invention relates to compositions of rosmarinic acid or its derivatives and to the use of a hydrolytic enzyme or of microorganism containing or producing hydrolytic enzymes in these compositions. The invention also pertains to methods for improving the biological effects of the rosemary extracts and for administering such compositions to a human or animal subject for improving the skin, coat, hair or health of the subject.05-27-2010
20110081320Treatment/Cure of Autoimmune Disease - An embodiment entails administering an effective amount of a product such as a protease or a source of a protease that destroys or deactivates an immunogen, mimic or antigen specific to a particular autoimmune disease before it encounters the immune system of a patient.04-07-2011
20100310520MICROORGANISMS FOR IMPROVING THE HEALTH OF INDIVIDUALS WITH DISORDERS RELATED TO GLUTEN INGESTION - The invention relates to microorganisms for the treatment of food allergies, specifically coeliac disease, as well as to methods for the selection thereof. The action mechanisms of said microorganisms include: (i) the regulation of the innate and adaptive immunological responses; (ii) the reduction of the concentration of toxic gluten peptide epitopes in the intestinal lumen; (iii) the strengthening of the barrier defence function against harmful antigens and bacteria; and (iv) the provision of enzymatic activities that promote digestion.12-09-2010
20100310519Incorporation of Active Molecules into Microalga - Process of incorporating active and aggressive molecules into a microalga, with targeted recognition of cancer cells. The invention relates to the incorporation of active molecules into a microalga having first developed a plasmid, and/or a gene with resistance to the specific molecules. The process of the invention is particularly intended for human and veterinary medicine.12-09-2010
20090022691BACTERIAL DELIVERY OF BIOLOGICALLY ACTIVE POLYPEPTIDES - The present invention relates to methods for the delivery of biologically active polypeptides to a subject by colonising non-pathogenic Gram negative bacteria. Also provided by this invention are methods of treating or preventing diseases by administering colonising Gram negative bacteria that express one or more biologically active polypeptides. The colonising non-pathogenic Gram negative bacteria may be administered in pharmaceutical formulations.01-22-2009
20090324552CONTROLLED RELEASE CYTOTOXIC AGENT COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with cytotoxic agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).12-31-2009
20090324551TLR AGONISTS - The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore.12-31-2009
20120201785USE OF BIFIDOBACTERIUM LONGUM FOR THE PREVENTION AND TREATMENT OF INFLAMMATION - The invention relates to the use, in the manufacture of a medicament or a therapeutic nutritional composition for preventing or reducing inflammation in a mammal, of 08-09-2012
20080254000Methods of Improving the Yield and/or Quality of Aquatic or Marine Animals - Methods of treating aquatic or marine animal water bodies including contacting the water body with one or more sulfur oxidizing bacteria such as those selected from the genus 10-16-2008
20110020285Composition Containing Cacao and Spirulina - The invention relates to a composition containing 01-27-2011
20110027233Prothioconazole Tolerant Cryptococcus Flavescens Strains for Biological Control of Fusarium Head Blight - Strains of 02-03-2011
20110027232Formulations of viable microorganisms and their methods of production and use - The present invention relates to formulations of viable microorganisms in a water insoluble, water-absorbent substance and methods of producing formulations of viable microorganisms. Also disclosed is a method of treating plants and/or plant seeds with the formulations of the present application.02-03-2011
20110135608USE OF PROBIOTIC BACTERIA FOR THE TREATMENT OF HYPERHOMOCYSTEINAEMIA - The present invention refers to the use of probiotic bacteria for the treatment of hyperhomocysteinaemia. The present invention furthermore refers to a composition comprising probiotic bacteria in association with at least one vitamin chosen from the group comprising the B group of vitamins for the treatment of plasma hyperhomocysteinaemia.06-09-2011
20110262400PROBIOTIC BACTERIAL MOLECULES AND THEIR USE IN METHODS TO TREAT/PREVENT INFECTION BY HARMFUL BACTERIA AND TO PROVIDE NUTRITIONAL HEALTH - This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.10-27-2011
20110052538PROBIOTIC/NON-PROBIOTIC COMBINATIONS - This invention pertains to a method of promoting gastrointestinal health by ingesting a composition comprising one or more probiotic microorganisms, one or more carbohydrate sources, and one or more resistant protein products. Large intestinal health is benefited by one or more of the following: increased fecal weight, lower fecal pH, increased carbohydrate fermentation, and amelioration of protein fermentation.03-03-2011
20100322904COMPOSITION COMPRISING BIFIDOBACTERIUM INFANTIS AND FRUCTO- AND GALACTO-OLIGOSACCHARIDES FOR THE PREVENTION OF INTESTINAL DISCOMFORT IN INFANTS - Compositions comprising bifidobacteria and galactooligosaccharides and fructooligosaccharides are provided that support the introduction of solid weaning foods in the diet of infants that receive infant milk formula or breast milk.12-23-2010
20110097307Compositions and Methods for Augmenting Kidney Function - The present invention provides a nutritional food product composed of a prebiotic and an isolated protein for use in reducing elevated levels of nitrogenous waste products in the blood and ameliorating renal failure.04-28-2011
20110177034PROBIOTIC BIFIDOBACTERIUM LONGUM - The invention relates to novel, probiotic, anti-inflammatory strains of 07-21-2011
20110189133SKIN TREATMENT COMPOSITIONS - This invention relates to 08-04-2011
20100189693Novel Pasteuria Strain - The subject invention provides a novel and advantageous strain of 07-29-2010
20110189134FERMENTATION PRODUCT CONTAINING EQUOL-PRODUCING MICROORGANISM HAVING MAINTAINED EQUOL-PRODUCING ABILITY, AND METHOD FOR PRODUCING SAME - An object of the present invention is to provide a fermented product containing equol-producing microorganisms in the state of living cells by which equol production ability is maintained.08-04-2011
20120308526Sonic Low Pressure Spray Drying - This invention provides methods of spray drying pharmaceutical powders from a vibrating nozzle at low pressures. The method can effectively spray dry thick or viscous solutions or suspensions to provide small uniform particles. The invention includes dry particle compositions prepared by methods of low pressure spraying from vibrating nozzles.12-06-2012
20120308527PREVENTION OF OPPORTUNISTIC INFECTIONS IN IMMUNE-COMPRISED SUBJECTS - This invention relates to a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic 12-06-2012
20120308525NUTRITIONAL COMPOSITIONS INCLUDING A HIGH PROTEIN COMPONENT AND EXOGENOUS NUCLEOTIDES - Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including a high protein component and one or more exogenous nucleotides. The nutritional compositions can be specifically used to accelerate and improve wound healing in a mammal.12-06-2012
20100221227NOVEL METHOD OF TREATING DISEASE - This invention relates to compositions comprising a bacterium of the genus 09-02-2010
20100233128Natural Skin Products Containing Dairy and Processes - A skincare product containing one or more dairy products, and one or more ingredients such as a natural oil, an herb, a fruit, a vegetable, a grain, honey, sea salt, egg yolk and mixtures thereof, for application to human skin in order to improve the well-being of said skin. The skincare product is applied to the skin in order to cleanse, beautify, promote attractiveness, and/or alter the feel or appearance of the skin. Furthermore, the skincare product is applied to the skin by rubbing, pouring, sprinkling, and/or spraying the skincare product onto the skin.09-16-2010
20080213225SULFUR-OXIDIZING PLANT GROWTH PROMOTING RHIZOBACTERIA FOR ENHANCED CANOLA PERFORMANCE - Described herein is the isolation and identification of a number of sulfur oxidizing plant growth promoting rhizobacteria: RAY12, identified as 09-04-2008
20110002891PROBIOTIC COMPOSITIONS AND PROCESS THEREOF - Probiotic composition(s) and/or process(es) thereof. Processes may include applying 01-06-2011
20090136454Anti-inflammatory activity from lactic acid bacteria - In the present invention, lactic acid bacteria produce soluble factors (such as peptides or proteins) that block inflammatory responses in a mechanism that depends on G proteins and is post-transcriptional to effectively block protein production or secretion by cells.05-28-2009
20110008292LACTOBACILLUS ACIDOPHILUS NUCLEIC ACIDS ENCODING FRUCTO-OLIGOSACCHARIDE UTILIZATION COMPOUNDS AND USES THEREOF - Fructooligosaccharide (FOS)-related protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, FOS-related fusion proteins, antigenic peptides, and anti-FOS-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and host cells into which the expression vectors have been introduced. Methods for producing the polypeptides of the invention and methods for their use are further disclosed.01-13-2011
20120039853CRYOPROTECTANTS FOR FREEZE DRYING OF LACTIC ACID BACTERIA - The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications. More in particular, the invention relates to the increased viability and long-term storage of recombinant bacteria capable of expressing heterologous proteins or peptides and administered to humans or animals for therapeutic or vaccination purposes.02-16-2012
20120064039Use of Guanylyl Cyclase C Agonists to Suppress Appetite - Compositions comprising a guanylyl cyclase C agonist formulated for sustained specific release of an amount effective to suppress appetite when administered orally to an individual are disclosed. Compositions comprising a guanylyl cyclase C agonist formulated for intravenous delivery in an amount effective to suppress appetite when administered intravenously to an individual are also disclosed. Methods of suppressing appetite in an individual are disclosed.03-15-2012
20110081319COMPOSITION AND USE OF PHYTO-PERCOLATE FOR TREATMENT OF DISEASE - This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The phyto-percolate is believed to contain an enzyme having proteolytic activity. The invention further relates to the use of the phyto-percolate in a variety of disease state.04-07-2011
20110020284PROBIOTIC BIFIDOBACTERIUM STRAINS - strain AH1206 or mutants or variants thereof are immunomodulatory following oral consumption and are useful in the prophylaxis and/or treatment of inflammatory activity for example undesirable gastrointestinal inflammatory activity such as inflammatory bowel disease.01-27-2011
20110318310METHOD FOR ENHANCING STEM CELL TRAFFICKING - Consumption of blue-green algae, or extracts thereof, enhances trafficking or homing of stem cells in animals by inducing a transient increase in the population of stem cells present in the animal's circulatory system. The animal may be healthy or suffering some disease or physiological condition.12-29-2011
20110318309EQUOL-PRODUCING BACTERIUM AND USE THEREOF - The present invention is directed to a microorganism having an ability of converting daidzein to equol in 24 hours of 50% or higher; a food/beverage or pharmaceutical composition containing the microorganism; an equol production method employing the microorganism; and a nucleic acid fragment which can specifically detect the microorganism.12-29-2011
20090028826BACTERIAL EXTRACTS CULTURED IN THERMAL WATERS FOR REDUCING BAGS AND/OR DARK CIRCLES AROUND THE EYES - Bags and/or dark circles around the eyes of individuals afflicted therewith are reduced by administering to such individuals thus effective amounts of at least one extract of a non-photosynthetic and non-fruiting filamentous bacterium cultured in a medium which includes at least one non-sulfurous mineral and/or thermal water, e.g., an extract derived from the bacterium 01-29-2009
20120301435PROBIOTIC BIFIDOBACTERIAL COMPOSITION IN ACCORDANCE WITH SECRETOR BLOOD GROUP STATUS - The present invention relates to a microbial or probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals of non-secretor blood group phenotype. The present invention further relates to a method of tailoring a microbial or probiotic composition based on the bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals non-secretor blood group phenotype.11-29-2012
20120058087DIAGNOSIS OF ENDOMETRITIS - The present invention relates to methods for diagnosing and treatment of a dormant infection of at least one pathogen. The invention further relates to a composition comprising an anti-dormancy factor as well as to said composition for use in a method of diagnosis or treatment and also to a method for manufacturing said composition. The invention further relates to a kit of parts comprising, inter alia, said composition. The invention also relates to a method for activating a dormant infection.03-08-2012
20120014923HYPOGLYCEMIC EFFECT ENHANCER - A hypoglycemic effect enhancer for enhancing the activity of an α-glucosidase inhibitor, the enhancer comprising at least one kind of bacteria selected from the group consisting of bifidobacteria, lactic acid bacteria, saccharifying bacteria, and butyric acid bacteria.01-19-2012
20100150873NOVEL BACTERIA AND USES THEREOF - The present invention relates to a novel bacterium 06-17-2010
20080311081Bacteria mediated gene silencing - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.12-18-2008
20100284973Use of a L. Casei Strain For the Preparation of a Composition for Inhibiting Mast Cell Activation - The present invention pertains to the field of prevention and treatment of chronic or acute diseases involving mast cells, such as allergy and some autoimmune diseases. More precisely, the present invention concerns the use of probiotics containing a 11-11-2010
20120207713PROBIOTIC BIFIDOBACTERIUM STRAINS - strain AH1206 or mutants or variants thereof are immunomodulatory following oral consumption and are useful in the prophylaxis and/or treatment of inflammatory activity for example undesirable gastrointestinal inflammatory activity such as inflammatory bowel disease.08-16-2012
20120156172NEW LACTIC ACID BACTERIA HAVING ITS INHIBITORY EFFECT ON AVIAN INFLUENZA VIRUS INFECTION AND COMPOSITION CONTAINING THE SAME - The present invention relates to a new microorganism 06-21-2012
20120251501Formulations for Promoting Stem Cell Nutrition - A a multivitamin and mineral dietary supplement includes a base composition of whole aphanizomenon flos-aqua, phycocyanin and phenylethylamine for promoting the body's natural production of stem cells. The production, support and maintenance of these stem cells is enhanced with vitamins and/or minerals. The vitamins and minerals when combined with the base composition promote good health, body repair and longevity.10-04-2012
20100092429Composition - The present invention provides a composition comprising: (a) one or more live 04-15-2010
20100247489USE OF A COMPOSITION MADE OF MINERAL NUTRIENTS AND OPTIONALLY ACETOGENIC AND/OR BUTYROGENIC BACTERIA IN ORDER TO AVOID OR REDUCE THE FORMATION OF GAS IN THE LARGE INTESTINE OF A MAMMAL AND THE RESULTING ABDOMINAL PROBLEMS - The present invention relates to a composition comprising one or more minerals selected from the group consisting of selenium, molybdenum or tungsten, which is carried out galenically or chemically in a way that the mineral or minerals are released completely or in part, just before, during or shortly after arrival at the large intestine, and their use in the manufacture of a medicament for administering to a mammal for the prevention or reduction of gas formation in the colon thus conditioned abdominal complaints, particularly bloatings, meteorism or abdominal cramps. Furthermore, the invention relates to a procedure for the isolation of acetogenic and butyrogenic bacterial strains that are suitable for therapeutic purposes outlined above.09-30-2010
20120128634USE OF COLLINSELLA AEROFACIENS FOR REDUCING BLOATING - The invention relates to compositions comprising 05-24-2012
20120128633USE OF COLLINSELLA AEROFACIENS FOR REDUCING BLOATING - The invention relates to compositions comprising 05-24-2012
20100209394MITOGEN ACTIVATED PROTEIN KINASE MODULATOR - The present invention describes the method of modulating MAPK pathways. Further more the invention describes the use of Mycobacterium w for modulation of MAPK pathway intermediates for treatment of MAPK mediated conditions.08-19-2010
20120315250PROBIOTIC BIFIDOBACTERIAL COMPOSITION IN ACCORDANCE WITH SECRETOR BLOOD GROUP STATUS - The present invention relates to a probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with non-secretor blood group phenotype. The present invention further relates to a method of tailoring a probiotic composition based on the bifidobacteria found from the intestine of at least one non-secretor individual.12-13-2012
20120219527COMPOSITIONS FOR REDUCING GASTRO-INTESTINAL METHANOGENESIS IN RUMINANTS - The present invention concerns the reduction of gastro-intestinal methanogenesis in ruminants with the aid of agents that compete for the hydrogen atoms required by methanogens during normal fermentation of ingested feed. The invention in one aspect resides in the findings that both nitrate reductive pathways as well as sulphate reductive pathways outcompete gastro-intestinal methanogenesis in ruminants and, that the methanogenesis reducing effects of nitrate and sulphate are completely additive. At the same time the combined administration of nitrate and sulphate was found to be fully effective to avoid or mitigate the potential problems of nitrite intoxication normally encountered when using nitrate alone, which effect is further enhanced, where necessary, by the addition of a nitrite reducing probiotic micoroorganism. Hence, products are provided comprising high amounts of a combination of a nitrate compound and a sulphate compound and optionally a nitrite reducing probiotic microorganism, as well as methods of reducing gastro-intestinal methanogenesis in ruminants using such compositions.08-30-2012
20120230957COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN - The present invention provides compositions and methods for treatment or prevention of pain resulting from infection, infection related pain, and non-infectious pain as well as treatment or prevention of infections or adverse health consequences associated with infections.09-13-2012
20120230956BIFIDOBACTERIUM LONGUM AND FUNCTIONAL GI DISORDERS - The present invention generally relates to the field of probiotic bacteria. In particular it relates to 09-13-2012
20120230955ARABINOXYLANS FOR MODULATING THE BARRIER FUNCTION OF THE INTESTINAL SURFACE - The present invention is directed to a particular arabinoxylan (“AX”) preparation and the finding that this preparation has a beneficial effect on the organization of the intestinal microbial community in the lumen and in particular at the site of the gut mucosa, where it modulates the barrier function of the intestinal surface, primarily by modulating the mucosa-associated microbial community towards a relative increase of health beneficial bacteria, such as bifidobacteria and lactobacilli. It is accordingly a first aspect of the present invention to provide said arabinoxylan preparation characterized in comprising isolated water-soluble arabinoxylans and the use thereof to improve functioning (e.g. barrier function) of the intestinal epithelium. Thus, in a further aspect the present invention provides compositions, both pharmaceutical and nutritional compositions, comprising said arabinoxylan preparations; in particular pharmaceuticals, medical foods, food supplements or food compositions, such as infant formula products, dairy products, bakery products or pastry products. The compositions optionally comprise probiotics such as 09-13-2012
20120213739METHOD TO GROW LAWSONIA INTRACELLULARIS BACTERIA IN PERSISTENTLY INFECTED MCCOY CELLS - The present invention pertains to a method to obtain McCoy cells persistently infected with 08-23-2012
20100172875OIL-IN-WATER EMULSION AND ITS USE FOR THE DELAYED RELEASE OF ACTIVE ELEMENTS - The present invention concerns the use of an oil-in-water emulsion where the interior of oil droplets exhibit interfaces, between lipophilic domains and hydrophilic or amphiphilic domains, due to the presence of a lipophilic additive solubilized inside the oil droplets and which is used for delayed release of active elements such that the release of at least one active element, which has a octanol/water partitioning coefficient logP higher than −1, corresponds to a higher Tmax than the Tmax obtained for the simple reference oil-in-water emulsion where no lipophilic additive is used.07-08-2010
20100172874GUT MICROBIOME AS A BIOMARKER AND THERAPEUTIC TARGET FOR TREATING OBESITY OR AN OBESITY RELATED DISORDER - The present invention relates to the gut microbiome as a biomarker and therapeutic target for energy harvesting, weight loss or gain, and/or obesity in a subject. In particular, the invention provides methods of altering and monitoring the relative abundance of 07-08-2010
20120171167ANTI-OBESITY AGENT, ANTI-OBESITY FOOD OR BEVERAGE, GLUCOSE TOLERANCE-AMELIORATING AGENT, AND FOOD OR BEVERAGE FOR AMELIORATION OF GLUCOSE TOLERANCE - An anti-obesity agent or a glucose tolerance-ameliorating agent containing a bacterium belonging to the genus 07-05-2012
20120171166SYNBIOTIC COMBINATION OF PROBIOTIC AND HUMAN MILK OLIGOSACCHARIDES TO PROMOTE GROWTH OF BENEFICIAL MICROBIOTA - Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, and children for improving gastrointestinal function and tolerance, as well as the growth of beneficial microbiota. Suitable additional methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.07-05-2012
20120171165HUMAN MILK OLIGOSACCHARIDES TO PROMOTE GROWTH OF BENEFICIAL BACTERIA - Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, and children for improving gastrointestinal function and tolerance, as well as the growth of beneficial bacteria. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.07-05-2012
20120171164USE OF NUTRITIONAL COMPOSITIONS INCLUDING LACTOFERRIN IN SUPPORTING RESISTANCE TO VIRAL RESPIRATORY TRACT INFECTIONS - The present disclosure relates to the use of nutritional compositions including lactoferrin in supporting resistance to a viral respiratory tract infection. The method includes administering to a human a nutritional composition comprising a fat or lipid source, a protein source and lactoferrin produced by a non-human source.07-05-2012
20120171163METHOD FOR INHIBITING A BACTERIAL INVASIVE MECHANISM USING A NUTRITIONAL COMPOSITION - A method for inhibiting a bacterial invasive mechanism involving administering to a human a nutritional composition including a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; about 0.1 to about 1 g/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide; at least about 10 mg/100 kCal of lactoferrin selected from the group consisting of non-human lactoferrin, human lactoferrin produced by a genetically modified organism, and combinations thereof.07-05-2012
20120177607OXIDATIVE STRESS RESISTANT BIFIDOBACTERIA - The present invention relates in general to the field of Bifidobacteria. In particular the present invention relates to the field of Bifidobacteria with an improved resistance to oxidative stress. The inventors have identified a Bifido bacterium that exhibits for example an improved H07-12-2012
20120177606LACTIC ACID BACTERIUM FOR INHIBITING PRODUCTION OF GASTRIC ACID AND GASTRIN - The present invention relates to a method of reducing the acid concentration within gastric fluid, suppressing a tendency towards a strongly acidic pH within the gastric fluid, and inhibiting the production of gastrin, by administering lived or killed lactic acid bacterium (such as 07-12-2012
20100272689Protease Having Algicidal Activity, Gene Encoding the Same and Algicidal Formulation Comprising the Same - The present invention relates to a protease having algicidal activity, a gene encoding the same and algicidal formulation comprising the same. The protease according to the present invention showed high algicidal activity. Therefore, the protease can be used treatment of red tide in marine region of red tide occurrence.10-28-2010
20090060879Oral Compositions, Products and Methods Of Use - The present invention comprises an oral composition. More particularly to a method of treating and preventing a respiratory tract infection and providing energy, relieving stress, and mood enhancing benefits to a human comprising: the steps of administering to a human a composition comprising from about 450 IU to about 500,000 IU of cholecalciferol, per dose of the composition.03-05-2009
20090060878Oral Compositions, Products And Methods Of Use - The present invention comprises an oral composition. More particularly to a method of treating and preventing a respiratory tract infection and providing energy, relieving stress, and mood enhancing benefits to a human comprising: the steps of administering to a human a composition comprising from about 450 IU to about 500,000 IU of cholecalciferol, per dose of the composition.03-05-2009
20090060876Orally Used Compatible Solutes Containing Agents - The invention relates to the use of compatible solutes, especially ectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3 diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), β-mannosylglycerate (firoin), β-mannosylglyceramide (firoin A), proline betaine and/or derivatives as well as combinations thereof for the production of an agent aimed at preventing and treating gastrointestinal and amyloidal diseases, with agents containing said active ingredients being disclosed as well.03-05-2009
20110044951COMPOSITIONS FOR PREPARING A COFFEE BEVERAGE COMPRISING HYDROLYSED CHLOROGENIC ACID - The invention relates to compositions for preparing a beverage, the compositions comprise a microorganism and/or an enzyme capable of hydrolysing chlorogenic acids of a coffee extract to phenolic acids. When a beverage prepared with the compositions of the invention is consumed chlorogenic acids present in coffee extract is hydrolysed to improve antioxidant and/or anti-inflammatory properties compared to a similar conventional beverage.02-24-2011
20110236354Symbiotic bacterial oncolysis-a beacon-based method for enhanced destruction of solid tumors-including both the tumor core and rim - Symbiotic bacterial oncolysis is a method to directly lyse and/or otherwise destroy the tumor core and rim of solid tumors using two (or more) phases of treatment. The first phase localizes with specificity for features of tumor microenvironment. The second (and/or subsequent) phase(s)—otherwise known as the SYMBIOT—localizes with specificity for features—designed, selected or inherent—of an earlier treatment phase (typically the phase 1). This earlier phase (typically phase 1) acts as a BEACON to help improve the specificity and/or localization of the subsequent—SYMBIOT—phases of treatment. Overall this should lead to improved solid tumor destruction relative to current art.09-29-2011
20120328574P38 INHIBITORS - The invention relates to novel p38 MAPK inhibitor which involves 12-27-2012
20110280840COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED DISORDERS BY CHARACTERIZING AND RESTORING MAMMALIAN BACTERIAL MICROBIOTA - The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.11-17-2011
20100215620THE CO-CULTURE METHOD OF SPHINGOMONAS SP. BACTERIAL STRAIN AND ASPERGILLUS SP. FUNGUS STRAIN, NEW ANTI-CANCER AND ANTIBIOTIC GLIONITRINS DERIVED FROM THIS CO-CULTURE METHOD, AND PHARMACEUTICAL COMPOSITION CONTAINING GLIONITRINS OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT - The present invention relates to a co-culture method of 08-26-2010
20130011368Metabolically Active Micro-Organisms and Methods for Their Production - The invention relates to a preparation of metabolically active bacteria, compositions comprising such a preparation, e.g., probiotic supplements or animal feeds, and to uses thereof, for example in the treatment of diseases affecting the intestinal microbial balance. Also described are a growth substrate for microorganisms comprising a mixture of complex and simple sugars and a process for the manufacture of preparations of metabolically active microorganisms using this growth substrate.01-10-2013
20110158951USE OF BLOOD GROUP STATUS II - Provided is a microbial or probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals of non-secretor blood group phenotype. Further provided is a method of tailoring a microbial or probiotic composition based on the bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals non-secretor blood group phenotype.06-30-2011
20110158950USE OF BLOOD GROUP STATUS I - Provided is a probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with non-secretor blood group phenotype. Further provided is a method of tailoring a probiotic composition based on the bifidobacteria found from the intestine of at least one non-secretor individual.06-30-2011
20110158949Metabolically active micro organisms and methods for their production - The invention relates to a preparation of metabolically active bacteria, compositions comprising such a preparation, e.g., probiotic supplements or animal feeds, and to uses thereof, for example in the treatment of diseases affecting the intestinal microbial balance. Also described are a growth substrate for microorganisms comprising a mixture of complex and simple sugars and a process for the manufacture of preparations of metabolically active microorganisms using this growth substrate.06-30-2011
20130022578METHODS AND SYSTEM FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONS - Provided herein are methods and systems for interfering with viability of bacteria and related compounds and compositions.01-24-2013
20080226603Prebiotic - Carbohydrates, in particular mannose containing carbohydrates, are used as a promotor of cell growth. Specifically, polysaccharide hydrolysates are shown to have superior efficacy in promoting the growth of cells, synbiotic foods, prebiotics and pharmaceutical compositions containing mannose containing carbohydrates and polysaccharide hydrolysates described.09-18-2008
20130171109ROTHIA SPECIES GLUTEN-DEGRADING ENZYMES AND USES THEREOF - There are gluten-degrading enzymes found in 07-04-2013
20120251500Anti-Aging Formulations - A dietary supplement based on blue green algae, phycocyanin and phenylethylamine is fortified with one or more of curcumin, silymarin, resveratrol, astragalus root extract, astragoloside IV, vitamin D3, vitamin C, anhydrous trimethylglycine and brewer's yeast to stimulate stem cell production and reduce the rate of telomere reduction or shortening. This can result in the repair of existing body cells and enhance longevity by stimulating the production of new stem cells and maintaining the telomeres on new stem cells as well as existing cells. The dietary supplement supports an increased life span by enhancing metabolic function, activating SIRT-1 anti-aging genes, and encouraging the production of new cells with longer telomeres.10-04-2012
20110268704ENHANCED SHELF LIFE AND ON SEED STABILIZATION OF LIQUID BACTERIUM INOCULANTS - The present invention includes a method for producing a liquid inoculant containing a desiccant. The method can improve survival and stability of bacteria in liquid inoculants in pack and on seeds. The method includes providing a liquid inoculant of a bacteria grown to a substantially stationary phase. A desiccant treatment containing a desiccant is added to the liquid inoculant to form a partially desiccated inoculant product. The partially desiccated inoculant product can be packaged and stored. The partially desiccated inoculant product can also be applied to seeds.11-03-2011
20130115195Anti-Aging Formulations - A dietary supplement based on fucoidan, blue-green algae, phycocyanin and phenylethylamine is fortified with one or more of curcumin, silymarin, resveratrol, astragalus root extract, astragoloside IV, vitamin D3, vitamin C, anhydrous trimethylglycine and brewers yeast to stimulate stem cell production and reduce the rate of telomere reduction or shortening. This can result in the repair of existing body cells and enhance longevity by stimulating the production of new stem cells and maintaining the telomeres on new stem cells as well as existing cells. The dietary supplement supports an increased life span by enhancing metabolic function, activating SIRT-1 anti-aging genes, and encouraging the production of new cells with longer telomeres.05-09-2013
20130101560USE OF ABO TYPE - The present invention relates to use of the ABO blood group genotype of an individual as a criterion for microbiota modulation that is tailored based on the differences in the spectrum of bacteria found between individuals with different ABO blood group genotypes. The present invention relates further to a microbial composition tailored based on the microbial genotypes shown to be specific for A, B, and/or O blood groups.04-25-2013
20130101559ANTI-MICROBIAL AGENT FROM PAENIBACILLUS SP. AND METHODS AND USES THEREOF - The present invention provides, in part, a 04-25-2013
20130129684METHOD OF INHIBITING METHANOGENESIS - The object of the present invention is to provide a technique to inhibit methanogens from producing methane. The use of 05-23-2013
20080241104ESPFU NUCLEIC ACIDS AND PROTEINS AND USES THEREOF - Disclosed are EspF10-02-2008
20120276060FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR TREATING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE - disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of 11-01-2012
20120276059FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR MONITORING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE - disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of 11-01-2012
20120276058METHANE REDUCING STRAINS AND METHODS OF USE - Strains and compositions of bacterium of the genus 11-01-2012
20120276057NUTRITIONAL COMPOSITION FOR SUPPORTING BRAIN DEVELOPMENT AND FUNCTION OF TODDLERS - The present invention relates to a nutritional composition, in particular directed to toddlers and/or a weaning child, said nutritional composition comprising a protein source, a source of available carbohydrates, a lipid source, at least one probiotic microorganism, and prebiotics, wherein said lipid source comprises DHA (docosahexaenoic acid). The nutritional composition improves cognitive performance, in particular learning and memory of the child. Preferably, the composition comprises sphingomyelin, sialic acid, choline, essential fatty acids and taurine.11-01-2012
20120276056Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine - The present invention relates to method of treating distal gastrointestinal diseases including infections, inflammations and functional motility disorders by oral administration of therapeutic or preventive biologic agent that is released directly to the disease area in the distal ileum, ileacecal junction or colon. The biologic agent may include live or dormant bacteria or other organism, e.g. yeast, or other biologic agent. The delivery vehicle must prevent release of the biologic agent in the upper segments of the gastrointestinal tract where it may lose its potency or decrease in quantity.11-01-2012
20100291038Novel Medicinal Formulation for Inducing an Immune Response in Patients with Chronic and Recurring Infections - A composition for the treatment of respiratory tract infection (RTI) comprising, a homogenized mixture of at least two serially diluted and potentized substances, as herein described, selected from: 1. 11-18-2010
20100303763METHOD FOR DECREASING ABDOMINAL GIRTH BY ADMINISTERING A BIFIDOBACTERIUM BACTERIA - A method for decreasing abdominal girth in a subject by administering a probiotic, preferably a bacteria of the 12-02-2010
20130156738BIFIDOBACTERIUM ADOLESCENTIS SPM0212 HAVING ANTIVIRAL ACTIVITY FOR HEPATITIS B VIRUS, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING HEPATITIS B COMPRISING THEREOF - The present invention relates to a 06-20-2013
20130156739PRODUCT FOR THE UPPER GASTRIC SPHERE - The invention concerns a product for the upper gastric sphere of humans. The product can address acidity in upper gastric sphere of humans. The product of the invention is typically to be administered orally, typically as food or food supplement. The product comprises a base product and several agents that provide benefits to the upper gastric sphere.06-20-2013
20130189228CYANO ANTHRANILAMIDE INSECTICIDES - This invention provides compounds of Formula 1, N-oxides and suitable salts thereof07-25-2013
20090162323Method for Stimulating the Intestinal Flora - The present invention relates to methods for feeding and to compositions to be administered to infants delivered via caesarian section and in particular to the use of a) at least two different microorganisms; or b) at least one microorganism and at least one indigestible oligosaccharide; or c) at least two different Bifidobacteria species, subspecies or strains for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. Thereby it is possible to stimulate the healthy development of the intestinal flora of said infants.06-25-2009
20120020927Bacterial Strains Having an Outstanding Ability to Produce Menaquinone - The invention relates to bacterial strains having an outstanding ability to produce menaquinone and to applications thereof.01-26-2012
20120020926COMPOSITION COMPRISING CAFTARIC ACID AND/OR DERIVATIVES THEREOF - The present invention relates generally to the field of food and drinks. In particular, for example, a composition is provided that allows to provide tartaric and/or caffeic acid to a subject. One embodiment of the present invention is a composition comprising an ingredient containing caftaric acid and/or derivatives thereof, and a lactic acid bacterium capable of hydrolysing caftaric acid and/or derivatives thereof to generate tartaric and/or caffeic acid.01-26-2012
20130195804COMPOSITIONS FOR FECAL FLORAL TRANSPLANTATION AND METHODS FOR MAKING AND USING THEM AND DEVICES FOR DELIVERING THEM - In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or 08-01-2013
20130195803BOVINE MILK OLIGOSACCHARIDES - Oligosaccharides from bovine milk, whey and dairy products, and methods of producing bovine milk oligosaccharides are provided.08-01-2013
20130095074USE OF CAFTARIC ACID AND LACTIC BACTERIUM IN FOOD SUPPLEMENT FOR REGULATING SKIN PIGMENTATION - The present invention relates generally to the field of cosmetic and/or food supplement. More specifically, the present invention aims to provide the use of at least an ingredient containing caftaric acid and/or derivatives and a micro-organism and/or an enzyme capable of hydrolyzing caftaric acid and/or derivatives thereof to generate tartaric and/or caffeic acid, for improving skin tone and preventing and/or treating hyper-pigmentation of skin and/or skin color imperfections such as age-spots and other skin disorders characterized by abnormal pigments. Also, the present invention aims at providing a skin lightening agent.04-18-2013
20120087896HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS - Novel hydroxylated 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising a hydroxylated 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.04-12-2012
20120087895Probiotic Therapies for Autism - Provided is a method and a composition for improving behavioral performance in an individual comprising identifying an individual in need of treatment, and providing such an individual a composition comprising bacteria within the genus 04-12-2012
20130209411Lactocepins For Use in the Treatment of IP-10-Mediated Inflammatory Diseases - The invention relates to lactocepins and/or a functionally active fragment thereof for use in the prophylaxis and/or the treatment of a disease and to one or more lactocepin(s) and/or one or more functionally active fragment(s) thereof for use in the prophylaxis and/or treatment of IP-10-mediated inflammatory diseases.08-15-2013
20130209412FERMENTED FOOD AND METHOD FOR PRODUCING SAME - The purpose of the present invention is to provide a technique whereby the flavor of products such as fermented milk that use the 08-15-2013

Patent applications in class Bacteria or actinomycetales

Patent applications in all subclasses Bacteria or actinomycetales